FamiCord AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VTIAF research report →
Companywww.vita34.de
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates.
- CEO
- Jakub Julian Baran
- IPO
- 2020
- Employees
- 783
- HQ
- Leipzig, DE
Price Chart
Valuation
- Market Cap
- $111.13M
- P/E
- -10.85
- P/S
- 0.78
- P/B
- 9.70
- EV/EBITDA
- 10.31
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 53.12%
- Op Margin
- -2.63%
- Net Margin
- -7.21%
- ROE
- -52.70%
- ROIC
- -2.00%
Growth & Income
- Revenue
- $88.14M · 7.25%
- Net Income
- $-6,300,638 · 48.08%
- EPS
- $-0.36 · 48.57%
- Op Income
- $-3,516,682
- FCF YoY
- -104.56%
Performance & Tape
- 52W High
- $7.00
- 52W Low
- $4.57
- 50D MA
- $6.38
- 200D MA
- $6.22
- Beta
- 0.62
- Avg Volume
- 22.392
Get TickerSpark's AI analysis on VTIAF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VTIAF Coverage
We haven't published any research on VTIAF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VTIAF Report →